Next 10 |
2024-06-24 09:22:18 ET More on Scholar Rock FOMC Meeting, Jobs Report, And Apple Earnings Headline Big Week Seeking Alpha’s Quant Rating on Scholar Rock Historical earnings data for Scholar Rock Financial information for Scholar Rock Read the...
2024-06-13 08:00:15 ET Etzer Darout from BMO Capital issued a price target of $31.00 for SRRK on 2024-06-13 07:24:00. The adjusted price target was set to $31.00. At the time of the announcement, SRRK was trading at $9.39. The overall price target consensus is at $28.50 ...
Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients Analysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling of the ORR highlighting a potential patient selection strategy ...
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3 rd , at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on Tuesday, June 4 th at 7:00 a.m. CDT/8:00 a.m. EDT Scholar Rock (NASDA...
2024-05-23 10:15:06 ET Piper Sandler analyst issues OVERWEIGHT recommendation for SRRK on May 23, 2024 08:34AM ET. The previous analyst recommendation was Overweight. SRRK was trading at $11.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Phase 2 EMBRAZE proof-of-concept trial designed to assess apitegromab's ability to safely preserve lean muscle mass in individuals on GLP-1 receptor agonist therapy for obesity New preclinical head-to-head comparison shows that SRK-439 is more potent than an anti-ActRII antibody in mainta...
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will host an Investor Da...
2024-05-14 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-07 13:53:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Scholar Rock Holding (NASDAQ: SRRK ) just reported results for the first quarter of 2024. Scholar Rock Holding reported earnings per share of -59 cents. This was below the...
2024-05-07 07:43:01 ET More on Scholar Rock FOMC Meeting, Jobs Report, And Apple Earnings Headline Big Week Seeking Alpha’s Quant Rating on Scholar Rock Historical earnings data for Scholar Rock Financial information for Scholar Rock Read the...
News, Short Squeeze, Breakout and More Instantly...
Scholar Rock Holding Corporation Company Name:
SRRK Stock Symbol:
NASDAQ Market:
Scholar Rock Holding Corporation Website:
2024-06-13 08:00:15 ET Etzer Darout from BMO Capital issued a price target of $31.00 for SRRK on 2024-06-13 07:24:00. The adjusted price target was set to $31.00. At the time of the announcement, SRRK was trading at $9.39. The overall price target consensus is at $28.50 ...
Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients Analysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling of the ORR highlighting a potential patient selection strategy ...
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3 rd , at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on Tuesday, June 4 th at 7:00 a.m. CDT/8:00 a.m. EDT Scholar Rock (NASDA...